Interleukin Genetics Inc. is touting a study it says shows the efficacy of its weight management genetic test.
The Waltham, Mass.-based genetic test developer said the one-year weight loss study of 101 overweight or obese premenopausal women showed that patients who adhered to a diet pegged to their genotype (as determined by Interleukin’s Inherent Health weight management genetic test) lost an average of 6.2 percent (13.2 lbs) in a year, compared with 2.4 percent (4.6 lbs) for patients assigned to “inappropriate” diets.
The Interleukin test divided patients into three genotype categories, according to their predisposition to respond to either low fat, low carbohydrate or macronutrient-balanced diets.
Patients on diets pegged to their genetic pre-dispositions also cut 6.5 percent from their waistlines (2.6 inches) in a year, compared with 3.2 percent (1.2 inches) for the other patients in the study.
Interleukin posted second-quarter sales of $223,000, down 57.3 percent compared with $522,000 during the same period last year.
Net losses widened 122 percent to $3.7 million, compared with $1.7 million during the 2008 second quarter. Some of the net loss ($1.4 million) stemmed from discontinued operations, including the Alan James Group.